High serum enalaprilat in chronic renal failure

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 2, Issue 4, 2001, Pages 240-245

  Elung Jensen, Thomas ^a   Heisterberg, Jens ^a   Kamper, Anne Lise ^a   Sonne, Jesper ^a   Strandgaard, Svend ^a   Larsen, Niels Erik ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Angiotensin I converting enzyme inhibitors; Chronic renal failure; Dosing guidelines; Enalapril; Enalaprilat; Pharmacokinetics

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ENALAPRILAT;

ADULT; AGED; ARTICLE; BLOOD; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; CROSS-SECTIONAL STUDY; FEMALE; GENETIC POLYMORPHISM; GENETICS; GENOTYPE; GLOMERULUS FILTRATION RATE; HUMAN; MALE; MIDDLE AGED; RENOVASCULAR HYPERTENSION;

ADULT; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CROSS-SECTIONAL STUDIES; ENALAPRIL; ENALAPRILAT; FEMALE; GENOTYPE; GLOMERULAR FILTRATION RATE; HUMANS; HYPERTENSION, RENAL; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PEPTIDYL-DIPEPTIDASE A; POLYMORPHISM, GENETIC;

EID: 0035528586     PISSN: 14703203     EISSN: None     Source Type: Journal    
DOI: 10.3317/jraas.2001.038     Document Type: Article

References (42)

1. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med 1997;157:2413-46.
2. Guidelines subcommittee. 1999 World Health Organization - International Society of Hypertension Guidelines for the Management of Hypertension. J Hypertens 1999;17(2):151-83.
3. Salvetti A, Mattel P, Sudano I. Renal Protection and Antihypertensive Drugs. Current Status. Drugs 1999;57:665-93.
4. Seyffart G. Drug Dosage in Renal Insufficiency, ed 1, Dordrecht, Kluwer Academic Publishers, 1991;218-9.
5. Hoyer J, Schulte KL, Lenz T. Clinical pharmacokinetics of angiotensin converting enzyme (ACE) inhibitors in renal failure. Clin Pharmacokinet 1993;24:230-54.
6. GISEN: Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Lancet 1997;349:1857-63.
7. Hannedouche T, Landais P, Goldfarb B et al. Randomised controlled trial of enalapril and beta blockers in non-diabetic chronic renal failure. BMJ 1994;309:833-7.
8. Ihle BU, Whitworth JA, Shahinfar S, Cnaan A, Kincaid-Smith PS, Decker GJ. Angiotensin-converting enzyme inhibition in nondiabetic progressive renal insufficiency: a controlled double-blind trial. Am J Kidney Dis 1996;27:489-95.
9. Kamper AL, Strandgaard S, Leyssac PP: Effect of enalapril on the progression of chronic renal failure. A randomized controlled trial. Am J Hypertens 1992;5:423-30.
10. Maschio G, Alberti D, Janin G et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med 1996;334:939-45.
11. Peters H, Ritz E. Dosing angiotensin II blockers-beyond blood pressure. Nephrol Dial Transplant 1999;14:2568-70.
12. Kampmann J, Siersbaek-Nielsen K, Kristensen M, Hansen JM. Rapid evaluation of creatinine clearance. Acta Med Scand 1974;196:517-20.
13. Brøchner-Mortensen J. A simple method for the determination of glomerular filtration rate. Scand J Clin Lab Invest 1972;30:271-1.
14. Lundberg P-A, Lindstedt G, Andersson T, Branegård B, Lundquister G, Nyström E. Single-Reagent Microcentrifugal Assay for Angiotensin Converting Enzyme in Serum. Clinical Chemistry 1984;30:163.
15. Lindpaintner K, Pfeffer MA, Kreutz R et al. A prospective evaluation of an angiotensin-converting-enzyme gene polymorphism and the risk of ischemic heart disease. N Engl J Med 1995;332:706-11.
16. Rowland M, Tozer TN. Clinical Pharmacokinetics. Concepts and Applications, ed 3, Williams & Wilkins, 1995.
17. Ulm EH, Hichens M, Gomez HJ et al. Enalapril maleate and a lysine analogue (MK-521): disposition in man. Br J Clin Pharmacol 1982;14:357-62.
18. Till AE, Gomez HJ, Hichens M et al. Pharmacokinetics of repeated single oral doses of enalapril maleate (MK-421) in normal volunteers. Biopharm Drug Dispos 1984;5:273-80.
19. Churg J, Cotran RS, Sinniah R, Sakaguchi H, Sobin L. Renal Disease: classification and atlas of tubulo-interstitial diseases. Tokyo, Igaru-Shoin, 185.
20. Anderson S, Meyer TW, Rennke HG, Brenner BM. Control of glomerular hypertension limits glomerular injury in rats with reduced renal mass. J Clin Invest 1985;76:612-19.
21. Lapinski R, Perico N, Remuzzi A, Sangalli F, Benigni A, Remuzzi G. Angiotensin II modulates glomerular capillary permselectivity in rat isolated perfused kidney. J Am Soc Nephrol 1996;7:653-60.
22. Kamper AL, Holstein RN, Leyssac PP, Strandgaard S. The influence of angiotensin-converting enzyme inhibition on renal tubular function in progressive chronic nephropathy. Am J Kidney Dis 1996;28:822-31.
23. Higashi Y, Oshima T, Sasaki S et al. Angiotensin-converting enzyme inhibition, but not calcium antagonism, improves a response of the renal vasculature to L-arginine in patients with essential hypertension. Hypertension 1998;32:16-24.
24. Wolf G, Haberstroh U, Neilson EG. Angiotensin II stimulates the proliferation and biosynthesis of type I collagen in cultured murine mesangial cells. Am J Pathol 1992;140:95-107.
25. Wolf G, Ziyadeh FN. The role of angiotensin II in diabetic nephropathy:emphasis on nonhemodynamic mechanisms. Am J Kidney Dis 1997;29:153-63.
26. Mimran A, Ribstein J, DuCailar G. Contrasting effect of anti-hypertensive treatment on the renal response to L-arginine. Hypertension 1995;26:937-41.
27. Keilani T, Danesh FR, Schlueter WA, Molteni A, Battle D. A subdepressor low dose of ramipril lowers urinary protein excretion without increasing plasma potassium. Am J Kidney Dis 1999;33:450-7.
28. Packer M, Poole-Wilson PA, Armstrong PW et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation 1999;100:2312-8.
29. Ajayi AA, Campbell BC, Kelman AW, Howie C, Meredith PA, Reid JL. Pharmacodynamics and population pharmacokinetics of enalapril and lisinopril. Int J Clin Pharmacol Res 1985;5:419-27.
30. Weisser K, Schloos J, Lehmann K, Dusing R, Vetter H, Mutschler E. Pharmacokinetics and converting enzyme inhibition after morning and evening administration of oral enalapril to healthy subjects. Eur J Clin Pharmacol 1991;40:95-9.
31. Fruncillo RJ, Rocci-ML J, Vlasses PH et al. Disposition of enalapril and enalaprilat in renal insufficiency. Kidney Int Suppl 1987;20:S117-S122.
32. Mujais SK, Quintanilla A, Zahid M, Koch K, Shaw W, Gibson T. Renal handling of enalaprilat. Am J Kidney Dis 1992;19:121-5.
33. Lowenthal DT, Irvin JD, Merrill D et al. The effect of renal function on enalapril kinetics. Clin Pharmacol Ther 1985;38:661-6.
34. Sica DA, Cutler RE, Parmer RJ, Ford NF. Comparison of the steady-state pharmacokinetics of fosinopril, lisinopril and enalapril in patients with chronic renal insufficiency. Clin Pharmacokinet 1991;20:420-7.
35. Edeki T, Johnston A, Li-Kam WE, Turner P. Enalapril pharmacokinetics and ACE inhibition, following single and chronic oral dosing. Int J Clin Pharmacol Ther 1994;32:142-6.
36. Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 1990;86:1343-6.
37. McLaughlin KJ, Harden PN, Ueda S, Boulton JJ, Connell JM, Jardine AG. The role of genetic polymorphisms of angiotensin-converting enzyme in the progression of renal diseases. Hypertension 1996;28:912-5.
38. Parving HH, Jacobsen P, Tarnow L et al. Effect of deletion polymorphism of angiotensin converting enzyme gene on progression of diabetic nephropathy during inhibition of angiotensin converting enzyme: observational follow up study. BMJ 1996;313:591-4.
39. Schmidt S, Strojek K, Grzeszczak W, Bergis K, Ritz E. Excess of DD homozygotes in haemodialysed patients with type II diabetes. The Diabetic Nephropathy Study Group. Nephrol Dial Transplant 1997;12:427-9.
40. Jacobsen P, Rossing K, Rossing P et al. Angiotensin converting enzyme gene polymorphism and ACE inhibition in diabetic nephropathy. Kidney Int 1998;53:1002-6.
41. Tarnow L, Parving HH, Jacobsen P et al. The significance of deletion polymorphism in the ACE gene for progression of diabetic nephropathies treated with ACE inhibitors. Ugeskr Laeger 1998;160:4886-9.
42. van Essen G, Rensma PL, de Zeeuw D et al. Association between angiotensin-converting-enzyme gene polymorphism and failure of renoprotective therapy. Lancet 1996;347:94-5.